The cut of prices on expired patent medicines up to 40%, decided by AIFA last week, "was a maneuver that the law asked to be carried out and which was done in the most balanced way possible, compatibly with the market situation ". The director general of Aifa, Guido Rasi, told Pharmakronos [in the picture], yesterday in Rome on the sidelines of the presentation of the book 'Gender Pharmacology'.
"I have already expressed and continue to express concern - continued Rasi - for the deconstruction of a market for which, but AIFA is already working on this together with the Regions, any maneuver must have two 'legs', one" which it rests "on prices, and one on volumes. We have acted on prices and are now evaluating how to work on the other fundamental part, which is volumes". As for the Antitrust report to Parliament on the need to organize single-lot tenders for the purchase of biologicals and biosimilars, based on the principle of bioequivalence, it is "fair and acceptable. Biosimilars are subjected to clinical studies which demonstrate their identical efficacy compared to the originator so we are also beyond the bioequivalence used for other drugs". And an official Aifa document should arrive shortly.
Barbara Di Chiara – April 6, 2011 – Pharmakronos
Equivalent prices. Federfarma Servizi writes to Aifa.
Aifa must issue the list of equivalents with updated prices as soon as possible based on the cuts given last week. This is the urgent invitation contained in the letter that Federfarma Servizi, the association that represents the intermediate distribution cooperatives, sent the day before yesterday to the general manager of
